Investigators at the University of Cincinnati have found a safe and effective treatment for life-threatening angioedema attacks in the emergency department.
In angioedema, patients experience a rapid swelling of the skin and subcutaneous tissues—which, in some cases, can lead to airway obstruction and suffocation. Physicians usually treat angioedema like an allergic reaction with corticosteroids and antihistamines.
But that therapy doesn’t always work for another version of the condition, thought to be caused by taking a class of drugs known as ACE inhibitors.
"ACE inhibitors are a common treatment in patients with congestive heart failure and hypertension,” says Joseph Moellman, MD, associate professor of emergency medicine. "It is also the most common etiology of patients presenting to the emergency department with angioedema.”
Moellman says there’s currently no treatment for ACE inhibitor induced (ACEI) angioedema, as the physiology of the condition is different—caused by the levels of the blood vessel-dilating peptide bradykinin in the body.
In a triple blind, placebo-controlled phase-2 trial, Moellman worked with professor of medicine and angioedema expert Jonathan Bernstein, MD, and fellow researchers at the UC Medical Center Emergency Department to study the drug Ecallantide in the treatment of ACEI angioedema that failed to respond to the conventional therapy of corticosteroids and antihistamines.
They wanted to see if Ecallantide, which has already safely treated acute attacks of hereditary angioedema, could help patients with ACEI angioedema—specifically, if it could make them eligible for discharge within four hours of treatment.
After enrolling 50 patients in the study, they found that patients treated with Ecallantide were more likely to meet discharge sooner than those receiving antihistamines and steroids—31 percent of Ecallantide patients were eligible for discharge within four hours, as compared with 21 percent of patients receiving placebos. Additionally, patients experienced few side effects from the medication.
Moellman says the data supports launching a phase-3 trial, which will enroll more patients to confirm the initial results. He is presenting the results at the annual meeting of the Society for Academic Emergency Medicine, held May 14-17 in Dallas.
Co-authors of the study include Christopher Lindsell, PhD, Kimberly Hart and Sean Collins, MD. The study was funded by Dyax, manufacturer of Ecallantide, or Kalibtor. Bernstein is a consultant and speaker for Dyax.
Kathryn Cosse | Eurek Alert!
Investigators may unlock mystery of how staph cells dodge the body's immune system
22.09.2017 | Cedars-Sinai Medical Center
Monitoring the heart's mitochondria to predict cardiac arrest?
21.09.2017 | Boston Children's Hospital
A warming planet
19.09.2017 | Event News
12.09.2017 | Event News
06.09.2017 | Event News
22.09.2017 | Life Sciences
22.09.2017 | Medical Engineering
22.09.2017 | Physics and Astronomy